Posted by Michael Wonder on 19 Aug 2020
US may need to look to Germany to reform drug pricing
19 August 2020 - US administrative and legislative efforts are moving the United States and Germany more into alignment on drug cost management philosophy, according to a review.
As prices for even long-established biologics rise by double digits in the United States, Germany has found success in controlling its prices through pricing restrictions, negotiations, and an abundance of biosimilar competition, according to a comparative article by James C. Robinson, PhD, MPH, the Leonard D. Schaeffer Professor of Health Economics and director of the Berkeley Center for Health Technology at the University of California, Berkeley.
